DBV Technologies (DBV) Q2 2024 earnings summary

Executive summary

• Viaskin Peanut, an epicutaneous immunotherapy patch, is in late-stage development for peanut-allergic children aged one to seven, with pivotal VITESSE Phase 3 trial for ages 4–7 and ongoing studies for toddlers aged 1–3.

• Regulatory engagement with the FDA continues for supplemental safety studies and a proposed labeling approach based on patch wear time experience.

• The company ended its collaboration with Nestlé Health Science; all operating income now derives from research tax credits.

• Cost-saving measures and operational changes, including an ADS ratio change and Nasdaq Capital Market transfer, have extended the cash runway into Q1 2025.

Financial highlights

• Cash and cash equivalents at June 30, 2024, were $66.2 million, down from $141.4 million at year-end 2023.

• Net loss for H1 2024 was $60.6 million, compared to $44.8 million in 2023, with loss per share at $(0.63).

• Operating income for H1 2024 was $2.6 million, mainly from research tax credits, down 43% year-over-year.

• Operating expenses rose to $65 million, up 28% year-over-year, driven by increased R&D and clinical activities.

• R&D expenses increased 39% to $46.8 million, reflecting VITESSE trial and COMFORT study preparations.

Outlook and guidance

• Cash runway is projected to last into Q1 2025, but substantial doubt exists about the ability to continue as a going concern without new funding.

• Additional capital will be sought through equity, debt, collaborations, or licensing to support R&D and potential product launch.

• VITESSE trial enrollment expected to complete by end of Q3 2024; topline results anticipated Q3 2025.

• Awaiting FDA feedback on proposed labeling for Viaskin Peanut in toddlers; study preparations continue.